Candel Therapeutics, Inc. (CADL) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US1374041093
Candel Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -48.27 m USD |
| EBIT | -36.06 m USD |
| Net income | -38.18 m USD |
| Diluted EPS – continuing operations | -0.72 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
More stocks
- Shenzhen Longli Technology Co Ltd Class A (300752.SZ)
- Foosung (093370.KS)
- Xinjiang Yilite Industry Co Ltd (600197.SS)
- Era Co Ltd (002641.SZ)
- Shandong Jincheng Pharmaceutical and Chemical Co Ltd (300233.SZ)
- Depo Auto Parts Industrial Co Ltd (6605.TW)
- Tron Inc. (TRON)
- Cowealth Medical China Co.Ltd. (603122.SS)
- Tainan Spinning Co Ltd (1440.TW)
- Pansoft Company Limited (300996.SZ)
- Klaveness Combination Carriers ASA (KCC.OL)
- New East New Materials Co Ltd (603110.SS)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.